leisure time -WSS

leisure time

author：focus 2025-09-28 23:31:09 - browse：27

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Pancreatic cancer is often deadly, but new discoveries are raising hope

WSS

Scientific mystery highlights the blind spots in genomics databases

Multiple sclerosis has subtypes with different best treatments: study

Bird flu in dairy cattle: New measures to control spread to humans

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

YouTube cracks down on misinformation on cancer treatment

Overprescribed: High cost isn't America's only drug problem

focus

leisure time

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Study: Black kids more likely to die after surgery than white kids

How one medical school became remarkably diverse

YouTube cracks down on misinformation on cancer treatment

Malaria cases in Florida and Texas: Here’s what you need to know

BMS, looking to build heart drug business, turns to AI for diagnosis

Jerome Adams on the need for new antivirals for Covid

Montana youths win climate lawsuit against state for promoting fossil fuels

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Megan Rapinoe shares emotional post following US Women's World Cup exit

explore

Gut bacteria may contribute to kidney autoimmunity, study finds

Surge in Apellis stock fueled by confidence in safety of its eye drug

Harvard scientists, with Google, unveil the most detailed brain map ever

Scientists uncover potential path to treating deadly childhood tumor

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Researchers test human milk's ability to repair gut microbiome

leisure time

entertainment

hotspot

entertainment